Super Specialty Hospital in India, International Standard Treatment

Patient's Experiences

Call Toll Free: UK: 0-808-234-6343 | US Canada: 1-800-730-6373

Wockhardt Corporate Office Wockhardt is amongst the leading pharmaceutical and biotechnology companies based out of India, with a market capitalization of $ 1.2 billion. With a strong Global footprint, today almost 60% of Wockhardt’s turnover comes out of International markets, most of it from Europe and the US.

To know more about Wockhardt visit www.wockhardt.com

Established nearly four decades ago, Wockhardt has built up a strong presence in the Healthcare business encompassing pharmaceutical formulations, bulk actives, biopharmaceuticals, vaccines and infant nutrition. Wockhardt is the only Indian pharmaceutical company to be selected as business “Superbrand” This "title" was awarded to Wockhardt by The Superbrands Council in recognition for offering consumers emotional and tangible benefits.

Wockhardt was rated among the Top 15 value creators (Source: Business World Nov ’03) in India and has a consistent track record of growth in sales (21% CAGR) and profitability (22% CAGR) over the last 10 years. Currently, Wockhardt has a consolidated group turnover of over USD 300 mn.

All Wockhardt plants including Sterile, API and Formulations are approved by various international regulatory authorities like USFDA, UK MHRA, Australian TGA etc.

RESEARCH & DEVELOPMENT

Wockhardt has been in the forefront of intellectual property creation and has filed about 150 patents thus far in various areas. It has identified a three pronged R&D programme that include:

Biotechnology and Bio-pharmaceuticals
Niche Generics &
New Drug Discovery

Biotechnology

Testing With nearly a decade of experience in biotechnology research, Wockhardt has built a competent team having end-to-end capabilities from “Concept to Market” in all facets of development and manufacture of recombinant biopharmaceuticals. These capabilities include gene cloning and construction of expression strains involving yeast, bacterial and mammalian cells. Wockhardt’s pioneering efforts in biotechnology have led to the launch three successful products in the Indian market – Biovac B (Hepatitis B Vaccine), Wepox (Erythropoeitin), and Wosulin (Recombinant Human Insulin). The company has also made a breakthrough with Interferon ?2b and Glargine (long acting insulin).

Generics

Wockhardt has an aggressive Abbreviated New Drug Application (ANDA) program which focuses on 3 strategic platforms for launching generics products in the advanced markets.

Injectables (Cephalosporins & Non-Cephalosporins)
Blockbuster molecules going off-patent
Value Added Generics (NDDS, Niche, follow-on Para IV)

New Chemical Entity

The primary focus of Wockhardt’s new drug discovery programme is anti-infectives. Amongst the many lead molecules, WCK-771, a broad-spectrum antibiotic for life threatening infections is already undergoing Phase II clinical trials while WCK-1152, a promising lead molecule for respiratory tract infections is undergoing Phase I clinical trials

BUSINESS

Business structure Wockhardt’s Business Model focuses on four core markets for growth viz. India, Europe, USA and lesser-regulated markets. This growth is driven through Wockhardt’s inherent strengths in marketing, alliances, and innovative research & development

Europe

Wockhardt has strategic presence in the key European markets of UK and Germany, which together account for 85% of the total European generic market. Wockhardt UK Limited is ranked amongst the top 10 generic companies in UK and is the largest Indian generic company. Wockhardt’s German subsidiary Esparma GmbH has a strong therapeutic presence in the segments of Urology, Neurology & Diabetology, which are high growth, high potential life style disease segments.

USA

In line with the company’s strategy of establishing presence in the world’s largest pharmaceutical market, Wockhardt has set up its own front-end (Sales, Marketing and Regulatory) infrastructure in the US. This would enable the company to capture value from end-to-end of the supply chain

ROW Countries

Wockhardt has set up comprehensive concept to market capabilities in Biotech for marketing biogenerics to the lesser-regulated markets

Regulatory & Marketing - Wockhardt has set up an impressive regulatory infrastructure for its biogeneric pipeline with registrations in developing markets of CIS & Latin America. The company has also set up front end offices in the identified markets: Either own organizations or strategic joint ventures or distribution arrangements.
Manufacturing - Wockhardt has set up a state of art Biotechnology Park at Aurangabad. The facility designed according to US FDA standards, will also house new biotechnology products that are currently under various stages of development. The facility has capacities to cater to 10-15 % of the global demand for major biopharmaceuticals.

India

The company has established a strong presence in the Indian market through a field force of over 1200 people who cover more than 1,50,000 doctors supported by a strong marketing and management team.

Six of its brands feature in the prestigious ORG Top 300 list in the country.

Acquisitions

Recognizing Europe’s exceptional heterogeneity as a catalyst for amplifying its global presence, Wockhardt has taken the inorganic route to growth in the European Union. The company has a track record of 3 successful acquisitions in Europe - Wallis Laboratories UK (1998), CP Pharmaceuticals UK (2003) and Esparma GmbH Germany (2004). With view to synergising its UK operations and building Wockhardt’s brand equity in UK, Wockhardt’s UK operations (CP Pharmaceuticals and Wallis laboratories) were integrated to form Wockhardt UK limited. Given Europe’s potential and the company’s expertise in acquisition management, Wockhardt is looking for growth through more acquisitions in Europe.